Oncology

Kadcyla Approved for Late-Stage Breast Cancer

The U.S. Food and Drug Administration today approved Kadcyla (ado-trastuzumab emtansine), a new therapy for patients with HER2-positive, late-stage (metastatic) breast cancer. HER2 is a protein involved in normal cell growth. It...

Read More

For latest news and updates
Email-id is invalid